Oliveira SM, et al. (2012) AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res 110, 1192-201 22456184

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T172-p - AMPKA2 (human) ▲

Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene Orthologous residues AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  myocyte-heart Cellular systems studied:  tissue Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ischemia increase acadesine increase compound_C acadesine inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, induced Comments:  increased cardiac contractility and Ca2+ sensitivity

S23-p - TNNI3 (human) ▲

Modsite: PAPIRRRssNyRAyA SwissProt Entrez-Gene Orthologous residues TNNI3 (human): S23‑p, TNNI3 (mouse): S23‑p, TNNI3 (rat): S23‑p, TNNI3 (rabbit): S22‑p, TNNI3 (dog): S23‑p, TNNI3 (cow): S24‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site Relevant cell lines - cell types - tissues:  myocyte-heart Cellular systems studied:  tissue Species studied:  mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE AMPKA1 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes acadesine no change compared to control acadesine, compound_C no change compared to control

S24-p - TNNI3 (human) ▲

Modsite: APIRRRssNyRAyAt SwissProt Entrez-Gene Orthologous residues TNNI3 (human): S24‑p, TNNI3 (mouse): S24‑p, TNNI3 (rat): S24‑p, TNNI3 (rabbit): S23‑p, TNNI3 (dog): S24‑p, TNNI3 (cow): S25‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site Relevant cell lines - cell types - tissues:  myocyte-heart Cellular systems studied:  tissue Species studied:  mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE AMPKA1 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes acadesine no change compared to control acadesine, compound_C no change compared to control

S42-p - TNNI3 (human) ▲
Modsite: AKKKskIsAsRKLQL SwissProt Entrez-Gene Orthologous residues TNNI3 (human): S42‑p, TNNI3 (mouse): S43‑p, TNNI3 (rat): S43‑p, TNNI3 (rabbit): S42‑p, TNNI3 (dog): S43‑p, TNNI3 (cow): S44‑p

S44-p - TNNI3 (human) ▲
Modsite: KKskIsAsRKLQLKt SwissProt Entrez-Gene Orthologous residues TNNI3 (human): S44‑p, TNNI3 (mouse): S45‑p, TNNI3 (rat): S45‑p, TNNI3 (rabbit): S44‑p, TNNI3 (dog): S45‑p, TNNI3 (cow): S46‑p

T143-p - TNNI3 (human) ▲
Modsite: RGKFKRPtLRRVrIs SwissProt Entrez-Gene Orthologous residues TNNI3 (human): T143‑p, TNNI3 (mouse): T144‑p, TNNI3 (rat): T144‑p, TNNI3 (rabbit): T143‑p, TNNI3 (dog): T144‑p, TNNI3 (cow): T145‑p

S150-p - TNNI3 (human) ▲

Modsite: tLRRVrIsADAMMQA SwissProt Entrez-Gene Orthologous residues TNNI3 (human): S150‑p, TNNI3 (mouse): S151‑p, TNNI3 (rat): S151‑p, TNNI3 (rabbit): S151‑p, TNNI3 (dog): S151‑p, TNNI3 (cow): S152‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  myocyte-heart Cellular systems studied:  tissue Species studied:  mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE AMPKA1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE AMPKA1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, pharmacological activator of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ischemia increase acadesine increase compound_C acadesine inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, induced Comments:  increased cardiac contractility and Ca2+ sensitivity